Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation

- We evaluated the combination of gefitinib and pemetrexed in EGFR-mutated NSCLC.
- The ORR and the median PFS were 84.6% and 18.0 m, respectively.
- The combination showed a tendency to be more effective in tumors with Del19.
- The hematological and non-hematological toxicities were mild.
- This regimen showed a high ORR, long median PFS, and acceptable toxicity.